TP53 and hypoplastic left heart syndrome: Thus, the inhibition of the RP–MDM2–p53 axis might be a therapeutic avenue to consider for functional intervention, although further studies are needed to identify the upstream mechanisms leading to the p53 pathway activation observed in HLHS proband cells.